KL-6 But Not CCL-18 Is a Predictor of Early Progression in Systemic Sclerosis-related Interstitial Lung Disease.
KL-6 But Not CCL-18 Is a Predictor of Early Progression in Systemic Sclerosis-related Interstitial Lung Disease.
复制标题
DOI：
10.3899/jrheum.170518
复制
发表时间：
2018-08
期刊：
影响因子：
--
通讯作者：
Assassi S
中科院分区：
文献类型：
--
作者：
Salazar GA;Kuwana M;Wu M;Estrada-Y-Martin RM;Ying J;Charles J;Mayes MD;Assassi S
2种肺蛋白KL-6和CCL-18是系统性硬化症（SSc）相关间质性肺病（ILD）的有前途的生物标志物。我们的目标是确定早期SSc-ILD患者随访第一年内用力肺活量%（FVC%）下降的预测意义。纳入了硬皮病结局研究（GENISOS）队列中入组的遗传学与环境的早期SSc患者（经成像证实为ILD）。基于基线和12-18个月内随访测量的FVC%的年变化率用作ILD进展的替代结局。研究了82例平均病程为2.3年的早期SSc-ILD患者。FVC%变化范围为-23%至38%。患者的基线KL-6水平高于健康对照（p < 0.0001）。KL-6水平越高，预测1年随访时FVC%下降越快（r =-0.23，p = 0.037）。使用先前发表的临界值1273 U/ml对KL-6进行分类后，其预测显著性在单变量模型中保持不变（B = −0.07，p = 0.01），表明KL-6阳性患者的FVC%年变化百分比平均下降7%。此外，在多变量模型中，在调整性别、疾病类型、抗Scl-70和免疫抑制治疗状态后，KL-6仍然是一个独立的预测因子。尽管CCL-18在患者中高于对照组（p < 0.001），但其水平不能预测FVC下降率（p = 0.458）。KL-6而非CCL-18可预测早期SSc-ILD进展。KL-6是一种有前景的肺蛋白，可有助于SSc-ILD临床试验的富集。
The 2 pneumoproteins, KL-6 and CCL-18, are promising biomarkers in systemic sclerosis (SSc)-related interstitial lung disease (ILD). Our goal was to determine their predictive significance for forced vital capacity % (FVC%) decline within the first year of followup in patients with early SSc-ILD. Early SSc patients with imaging-verified ILD enrolled in the Genetics versus Environment in Scleroderma Outcome Study (GENISOS) cohort were included. Annualized rate of change in FVC% based on the baseline and followup measurement within 12–18 months was used as the surrogate outcomes for ILD progression. Eighty-two early SSc-ILD patients with mean disease duration of 2.3 years were investigated. FVC% change ranged from −23% to 38%. Baseline KL-6 levels were higher in patients than healthy controls (p < 0.0001). Higher KL-6 levels were predictive of faster FVC% decline at the 1-year followup (r = −0.23, p = 0.037). Upon categorizing KL-6 using a previously published cutoff of 1273 U/ml, its predictive significance remained in the univariable model (b = −0.07, p = 0.01), indicating that patients with positive KL-6 had on average 7% more decline in annualized percent change of FVC%. Moreover, KL-6 remained an independent predictor after adjustment for sex, disease type, anti-Scl-70, and immunosuppressive treatment status in multivariable models. Although CCL-18 was higher in patients than controls (p < 0.001), its levels did not predict FVC decline rate (p = 0.458). KL-6 but not CCL-18 is predictive of early SSc-ILD progression. KL-6 is a promising pneumoprotein that can contribute to SSc-ILD clinical trial enrichment.
登录
查看更多内容
影响因子：
4.7
作者：
Assassi, Shervin;del Junco, Deborah;Sutter, Kari;McNearney, Terry A.;Reveille, John D.;Karnavas, Andrew;Gourh, Pravitt;Estrada-Y-Martin, Rosa M.;Fischbach, Michael;Arnett, Frank C.;Mayes, Maureen D.
通讯作者：
Mayes, Maureen D.
影响因子：
27.4
作者：
van den Hoogen, Frank;Khanna, Dinesh;Pope, Janet E.
通讯作者：
Pope, Janet E.
影响因子：
--
作者：
Prasse, Antje;Pechkovsky, Dmitri V.;Mueller-Quernheirn, Joachim
通讯作者：
Mueller-Quernheirn, Joachim
影响因子：
9.6
作者：
Hoffmann-Vold, Anna-Maria;Tennoe, Anders Heiervang;Molberg, Oyvind
通讯作者：
Molberg, Oyvind
影响因子：
27.4
作者：
Steen, Virginia D.;Medsger, Thomas A.
通讯作者：
Medsger, Thomas A.